CommercialCoverageMedium impact
08.02.47, linvoseltamab-gcpt (Lynozyfic™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
This is a new pharmacy policy effective 10/20/2025 for linvoseltamab-gcpt (Lynozyfic™), a recently FDA-approved bispecific antibody. The policy establishes coverage criteria, prior authorization requirements, and billing guidelines for this new oncology therapeutic agent. Billing teams must implement prior authorization protocols and ensure claims are submitted with appropriate diagnosis codes supporting medical necessity.
Action Required
By 10/20/2025: Pharmacy and billing teams must review policy 08.02.47 at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=10&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-02-47 to identify specific prior authorization requirements, covered indications, and any quantity limits or step therapy protocols for linvoseltamab-gcpt (Lynozyfic™). Update billing system with prior auth triggers, ensure pharmacy staff are trained on coverage criteria, and communicate with oncology providers regarding approval processes. Implement claim submission requirements per policy specifications to avoid denials. Impact is medium because this affects a new specialty drug with limited current utilization but requires immediate workflow implementation.